These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28904053)

  • 1. Cardiovascular Biomarkers in Hypertensive Patients with Medical Treatment-Results from the Randomized TEAMSTA Protect I Trial.
    Jagodzinski A; Neumann JT; Ojeda F; Sörensen NA; Wild P; Münzel T; Zeller T; Westermann D; Blankenberg S
    Clin Chem; 2017 Dec; 63(12):1877-1885. PubMed ID: 28904053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the Impact of Biomarker-Guided Versus ASCVD Risk-Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004.
    Foti K; Wang D; Tang O; Daya NR; Commodore-Mensah Y; Juraschek SP; Christenson RH; Selvin E; McEvoy JW
    Hypertension; 2024 Jul; 81(7):1599-1608. PubMed ID: 38690651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study).
    Madan N; Lee AK; Matsushita K; Hoogeveen RC; Ballantyne CM; Selvin E; McEvoy JW
    Am J Cardiol; 2019 Jul; 124(2):245-252. PubMed ID: 31088661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study.
    Sung KC; Oh YS; Cha DH; Hong SJ; Won KH; Yoo KD; Rha SW; Ahn YK; Ahn JC; Jang JY; Hong TJ; Cho SK; Park SH; Hyon MS; Nam CW; Chae IH; Yoo BS; Song JM; Jeong JO; Yoon YW; Kim BS; Yang TH; Cho DK; Kim SH; Choi YJ; Ahn JH; Jeon DW; Kim HS
    Clin Ther; 2018 Jan; 40(1):50-63.e3. PubMed ID: 29248384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in high-sensitive cardiac troponin T on hypertensive treatment.
    Hoshide S; Fukutomi M; Eguchi K; Watanabe T; Kabutoya T; Kario K
    Clin Exp Hypertens; 2013; 35(1):40-4. PubMed ID: 22631049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    Clin Chem; 2010 Nov; 56(11):1718-24. PubMed ID: 20844063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: a pilot prospective observational study.
    Voroneanu L; Siriopol D; Nistor I; Apetrii M; Hogas S; Onofriescu M; Covic A
    Kidney Blood Press Res; 2014; 39(6):636-47. PubMed ID: 25571877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP.
    Kopec M; Duma A; Helwani MA; Brown J; Brown F; Gage BF; Gibson DW; Miller JP; Novak E; Jaffe AS; Apple FS; Scott MG; Nagele P
    Anesth Analg; 2017 Feb; 124(2):398-405. PubMed ID: 28002165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death.
    Apple FS; Murakami MM; Pearce LA; Herzog CA
    Clin Chem; 2004 Dec; 50(12):2279-85. PubMed ID: 15364888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis.
    Pandey A; Patel KV; Vongpatanasin W; Ayers C; Berry JD; Mentz RJ; Blaha MJ; McEvoy JW; Muntner P; Vaduganathan M; Correa A; Butler J; Shimbo D; Nambi V; deFilippi C; Seliger SL; Ballantyne CM; Selvin E; de Lemos JA; Joshi PH
    Circulation; 2019 Dec; 140(25):2076-2088. PubMed ID: 31707797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
    Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
    Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis.
    Gravning J; Smedsrud MK; Omland T; Eek C; Skulstad H; Aaberge L; Bendz B; Kjekshus J; Mørkrid L; Edvardsen T
    Am Heart J; 2013 May; 165(5):716-24. PubMed ID: 23622908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-specific associations of established and emerging cardiac biomarkers with all-cause mortality in older adults: the ActiFE study.
    Dallmeier D; Denkinger M; Peter R; Rapp K; Jaffe AS; Koenig W; Rothenbacher D;
    Clin Chem; 2015 Feb; 61(2):389-99. PubMed ID: 25501933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure.
    Tsutamoto T; Kawahara C; Nishiyama K; Yamaji M; Fujii M; Yamamoto T; Horie M
    Am Heart J; 2010 Jan; 159(1):63-7. PubMed ID: 20102868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
    Martinez-Martin FJ; Rodriguez-Rosas H; Peiro-Martinez I; Soriano-Perera P; Pedrianes-Martin P; Comi-Diaz C
    J Hum Hypertens; 2011 Jun; 25(6):346-53. PubMed ID: 21107432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide.
    Avouac J; Meune C; Chenevier-Gobeaux C; Borderie D; Lefevre G; Kahan A; Allanore Y
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):1022-30. PubMed ID: 25604469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.